WelzelTMHinrichsenHSarrazinCet al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C registry. J Viral Hepat. 2017;24:840–849.
2.
NaranjoCABustoUSellersEMet al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154
3.
FerenciPBernsteinDLalezariJet al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-1992. doi:10.1056/NEJMoa1402338
4.
FlisiakRJanczewskaEWawrzynowicz-SyczewskaMet al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44:946-956. doi:10.1111/apt.13790
5.
Muñoz-GómezRRincónDAhumadaAet al. Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: a multicentre experience. J Viral Hepat. 2017;24:464-471. doi:10.1111/jvh.12664
